Pliant Therapeutics Reduces Workforce as Part of Strategic Realignment

Dow Jones

May 02

By Stephen Nakrosis

Pliant Therapeutics said it would reduce its current workforce by about 45%, part of a strategic realignment to position the company for execution of late stage clinical trials.

The company said Thursday its strategic restructuring and other cost-saving actions will extend its cash runway to support execution of late stage clinical trials.

Pliant is currently waiting for topline data from the BEACON-IPF Phase 2b/3 trial of bexotegrast to patients with idiopathic pulmonary fibrosis, a respiratory system illness. Once available, the company will evaluate the final dataset and determine next steps for bexotegrast's development, it said.

Bexotegrast has received fast track designation from the Food and Drug Administration and orphan drug designation from the FDA and the European Medicines Agency.

The restructuring will impact all departments, and the process is expected to be substantially completed by the end of the second quarter, Pliant said.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

May 01, 2025 17:45 ET (21:45 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2532783943"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2532783943\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2532783943?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-02 05:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2532783943","market":"sg","top_or_hot":-1,"title":"Pliant Therapeutics Reduces Workforce as Part of Strategic Realignment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Pliant <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said it would reduce its current workforce by about 45%, part of a strategic realignment to position the company for execution of late stage clinical trials. \n</p>\n<p>\n  The company said Thursday its strategic restructuring and other cost-saving actions will extend its cash runway to support execution of late stage clinical trials. \n</p>\n<p>\n  Pliant is currently waiting for topline data from the BEACON-IPF Phase 2b/3 trial of bexotegrast to patients with idiopathic pulmonary fibrosis, a respiratory system illness. Once available, the company will evaluate the final dataset and determine next steps for bexotegrast's development, it said. \n</p>\n<p>\n  Bexotegrast has received fast track designation from the Food and Drug Administration and orphan drug designation from the FDA and the European Medicines Agency. \n</p>\n<p>\n  The restructuring will impact all departments, and the process is expected to be substantially completed by the end of the second quarter, Pliant said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 01, 2025 17:45 ET (21:45 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pliant Therapeutics Reduces Workforce as Part of Strategic Realignment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPliant Therapeutics Reduces Workforce as Part of Strategic Realignment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-02 05:45</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Pliant <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said it would reduce its current workforce by about 45%, part of a strategic realignment to position the company for execution of late stage clinical trials. \n</p>\n<p>\n  The company said Thursday its strategic restructuring and other cost-saving actions will extend its cash runway to support execution of late stage clinical trials. \n</p>\n<p>\n  Pliant is currently waiting for topline data from the BEACON-IPF Phase 2b/3 trial of bexotegrast to patients with idiopathic pulmonary fibrosis, a respiratory system illness. Once available, the company will evaluate the final dataset and determine next steps for bexotegrast's development, it said. \n</p>\n<p>\n  Bexotegrast has received fast track designation from the Food and Drug Administration and orphan drug designation from the FDA and the European Medicines Agency. \n</p>\n<p>\n  The restructuring will impact all departments, and the process is expected to be substantially completed by the end of the second quarter, Pliant said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 01, 2025 17:45 ET (21:45 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2532783943","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2532783943","pubTimestamp":1746135900,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Pliant Therapeutics said it would reduce its current workforce by about 45%, part of a strategic realignment to position the company for execution of late stage clinical trials.The company said Thursday its strategic restructuring and other cost-saving actions will extend its cash runway to support execution of late stage clinical trials.Pliant is currently waiting for topline data from the BEACON-IPF Phase 2b/3 trial of bexotegrast to patients with idiopathic pulmonary fibrosis, a respiratory system illness. Once available, the company will evaluate the final dataset and determine next steps for bexotegrast's development, it said.Bexotegrast has received fast track designation from the Food and Drug Administration and orphan drug designation from the FDA and the European Medicines Agency.The restructuring will impact all departments, and the process is expected to be substantially completed by the end of the second quarter, Pliant said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LENZ":"Therapeutics","PLRX":"Pliant Therapeutics, Inc.","BK4007":"制药"},"translate_title":"作为战略调整的一部分，Pliant Therapeutics裁员","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"PLRX":0.9},"content_text":"By Stephen Nakrosis \n\n\n \n\n\n  Pliant Therapeutics said it would reduce its current workforce by about 45%, part of a strategic realignment to position the company for execution of late stage clinical trials. \n\n\n  The company said Thursday its strategic restructuring and other cost-saving actions will extend its cash runway to support execution of late stage clinical trials. \n\n\n  Pliant is currently waiting for topline data from the BEACON-IPF Phase 2b/3 trial of bexotegrast to patients with idiopathic pulmonary fibrosis, a respiratory system illness. Once available, the company will evaluate the final dataset and determine next steps for bexotegrast's development, it said. \n\n\n  Bexotegrast has received fast track designation from the Food and Drug Administration and orphan drug designation from the FDA and the European Medicines Agency. \n\n\n  The restructuring will impact all departments, and the process is expected to be substantially completed by the end of the second quarter, Pliant said. \n\n\n \n\n\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 01, 2025 17:45 ET (21:45 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}